Medicines and Healthcare products Regulatory Agency
Certificate of GMP Compliance Of A Manufacturer(1),(2)
Regulation 5 of the current Veterinary Medicines Regulations
The competent authority of United Kingdom confirms the following :Is an active substance manufacturer that has been inspected in accordance with Regulation 327 of The Human Medicines Regulations 2012 (SI 2012/1916).
From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on 09/03/2020, it is considered that it complies with
- The principles of GMP for active substances referred to in Regulation B17 and C17 of the Human Medicines Regulations 2012 (SI 2012/1916)
This certificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than three years have elapsed since the date of that inspection. However, this period of validity may be reduced or extended using regulatory risk management principles by an entry in the Restrictions or Clarifying remarks field. This certificate is valid only when presented with all pages and both Parts 1 and 2. The authenticity of this certificate may be verified in MHRA-GMDP. If it does not appear, please contact the issuing authority.
- (1) Guidance on the interpretation of this template can be found in the Help menu of MHRA-GMDP database.
- (2) These requirements fulfil the GMP recommendations of WHO.
Manufacture of active substance. Names of substances subject to inspection:
- [1000002292] VALSARTAN
- [1000007360] FAMCICLOVIR
- [1000016641] BENZONATATE
- [1000003329] OXCARBAZEPINE
- [2000009017] DICLOFENAC DIETHYLAMINE
- [1000003597] TRIBENOSIDE
- [3000018331] SACUBITRIL VALSARTAN SODIUM HYDRATE
- [1000010266] VILDAGLIPTIN
- [3000017086] TERBINAFINE BASE
- [2000005773] DICLOFENAC POTASSIUM
- [2000007108] ALISKIREN HEMIFUMARATE
- [2000007774] DICLOFENAC SODIUM
- [4000014593] RIBOCICLIB SUCCINATE
- [1000000958] LUMIRACOXIB
- [2000009969] PAZOPANIB HYDROCHLORIDE
- [1000001119] TELBIVUDINE
- [3000008741] DICLOFENAC FREE ACID
- [2000008305] METHYLPHENIDATE HYDROCHLORIDE
3. MANUFACTURING OPERATIONS - ACTIVE SUBSTANCES | |
VALSARTAN | |
3.1 | Manufacture of Active Substance by Chemical Synthesis |
3.1.1 Manufacture Of Active Substance Intermediates | |
3.1.2 Manufacture Of Crude Active Substance | |
3.1.3 Salt Formation/Purification steps (eg. Crystallisation) Crystallisation | |
3.5 | General Finishing Steps |
3.5.1 Physical Processing Steps milling | |
3.5.2 Primary Packaging | |
3.5.3 Secondary Packaging | |
3.6 | Quality Control Testing |
3.6.1 Physical / Chemical testing | |
3.6.2 Microbiological testing (excluding sterility testing) | |
FAMCICLOVIR | |
3.1 | Manufacture of Active Substance by Chemical Synthesis |
3.1.1 Manufacture Of Active Substance Intermediates | |
3.1.2 Manufacture Of Crude Active Substance | |
3.1.3 Salt Formation/Purification steps (eg. Crystallisation) Crystallisation | |
3.5 | General Finishing Steps |
3.5.2 Primary Packaging | |
3.5.3 Secondary Packaging | |
3.6 | Quality Control Testing |
3.6.1 Physical / Chemical testing | |
3.6.2 Microbiological testing (excluding sterility testing) | |
BENZONATATE | |
3.1 | Manufacture of Active Substance by Chemical Synthesis |
3.1.1 Manufacture Of Active Substance Intermediates | |
3.1.2 Manufacture Of Crude Active Substance | |
3.5 | General Finishing Steps |
3.5.2 Primary Packaging | |
3.6 | Quality Control Testing |
3.6.1 Physical / Chemical testing | |
3.6.2 Microbiological testing (excluding sterility testing) | |
OXCARBAZEPINE | |
3.1 | Manufacture of Active Substance by Chemical Synthesis |
3.1.1 Manufacture Of Active Substance Intermediates | |
3.1.2 Manufacture Of Crude Active Substance | |
3.1.3 Salt Formation/Purification steps (eg. Crystallisation) Crystallisation | |
3.5 | General Finishing Steps |
3.5.1 Physical Processing Steps milling | |
3.5.2 Primary Packaging | |
3.5.3 Secondary Packaging | |
3.6 | Quality Control Testing |
3.6.1 Physical / Chemical testing | |
3.6.2 Microbiological testing (excluding sterility testing) | |
DICLOFENAC DIETHYLAMINE | |
3.1 | Manufacture of Active Substance by Chemical Synthesis |
3.1.1 Manufacture Of Active Substance Intermediates | |
3.1.2 Manufacture Of Crude Active Substance | |
3.1.3 Salt Formation/Purification steps (eg. Crystallisation) Crystallisation | |
3.5 | General Finishing Steps |
3.5.2 Primary Packaging | |
3.5.3 Secondary Packaging | |
3.6 | Quality Control Testing |
3.6.1 Physical / Chemical testing | |
3.6.2 Microbiological testing (excluding sterility testing) | |
TRIBENOSIDE | |
3.1 | Manufacture of Active Substance by Chemical Synthesis |
3.1.1 Manufacture Of Active Substance Intermediates | |
3.1.2 Manufacture Of Crude Active Substance | |
3.5 | General Finishing Steps |
3.5.2 Primary Packaging | |
3.6 | Quality Control Testing |
3.6.1 Physical / Chemical testing | |
3.6.2 Microbiological testing (excluding sterility testing) | |
SACUBITRIL VALSARTAN SODIUM HYDRATE | |
3.1 | Manufacture of Active Substance by Chemical Synthesis |
3.1.1 Manufacture Of Active Substance Intermediates | |
3.1.2 Manufacture Of Crude Active Substance | |
3.1.3 Salt Formation/Purification steps (eg. Crystallisation) Crystallisation | |
3.5 | General Finishing Steps |
3.5.2 Primary Packaging | |
3.5.3 Secondary Packaging | |
3.6 | Quality Control Testing |
3.6.1 Physical / Chemical testing | |
3.6.2 Microbiological testing (excluding sterility testing) | |
VILDAGLIPTIN | |
3.1 | Manufacture of Active Substance by Chemical Synthesis |
3.1.1 Manufacture Of Active Substance Intermediates | |
3.1.2 Manufacture Of Crude Active Substance | |
3.1.3 Salt Formation/Purification steps (eg. Crystallisation) Crystallisation | |
3.5 | General Finishing Steps |
3.5.2 Primary Packaging | |
3.5.3 Secondary Packaging | |
3.6 | Quality Control Testing |
3.6.1 Physical / Chemical testing | |
3.6.2 Microbiological testing (excluding sterility testing) | |
TERBINAFINE BASE | |
3.1 | Manufacture of Active Substance by Chemical Synthesis |
3.1.1 Manufacture Of Active Substance Intermediates | |
3.1.2 Manufacture Of Crude Active Substance | |
3.1.3 Salt Formation/Purification steps (eg. Crystallisation) Crystallisation | |
3.5 | General Finishing Steps |
3.5.2 Primary Packaging | |
3.5.3 Secondary Packaging | |
3.6 | Quality Control Testing |
3.6.1 Physical / Chemical testing | |
3.6.2 Microbiological testing (excluding sterility testing) | |
DICLOFENAC POTASSIUM | |
3.1 | Manufacture of Active Substance by Chemical Synthesis |
3.1.1 Manufacture Of Active Substance Intermediates | |
3.1.2 Manufacture Of Crude Active Substance | |
3.1.3 Salt Formation/Purification steps (eg. Crystallisation) Crystallisation | |
3.5 | General Finishing Steps |
3.5.2 Primary Packaging | |
3.5.3 Secondary Packaging | |
3.6 | Quality Control Testing |
3.6.1 Physical / Chemical testing | |
3.6.2 Microbiological testing (excluding sterility testing) | |
ALISKIREN HEMIFUMARATE | |
3.1 | Manufacture of Active Substance by Chemical Synthesis |
3.1.1 Manufacture Of Active Substance Intermediates | |
3.1.2 Manufacture Of Crude Active Substance | |
3.1.3 Salt Formation/Purification steps (eg. Crystallisation) Crystallisation | |
3.5 | General Finishing Steps |
3.5.2 Primary Packaging | |
3.5.3 Secondary Packaging | |
3.6 | Quality Control Testing |
3.6.1 Physical / Chemical testing | |
DICLOFENAC SODIUM | |
3.1 | Manufacture of Active Substance by Chemical Synthesis |
3.1.1 Manufacture Of Active Substance Intermediates | |
3.1.2 Manufacture Of Crude Active Substance | |
3.1.3 Salt Formation/Purification steps (eg. Crystallisation) Crystallisation | |
3.5 | General Finishing Steps |
3.5.2 Primary Packaging | |
3.5.3 Secondary Packaging | |
3.6 | Quality Control Testing |
3.6.1 Physical / Chemical testing | |
3.6.2 Microbiological testing (excluding sterility testing) | |
RIBOCICLIB SUCCINATE | |
3.1 | Manufacture of Active Substance by Chemical Synthesis |
3.1.1 Manufacture Of Active Substance Intermediates | |
3.1.2 Manufacture Of Crude Active Substance | |
3.1.3 Salt Formation/Purification steps (eg. Crystallisation) Crystallisation | |
3.5 | General Finishing Steps |
3.5.1 Physical Processing Steps sieving | |
3.5.2 Primary Packaging | |
3.5.3 Secondary Packaging | |
3.6 | Quality Control Testing |
3.6.1 Physical / Chemical testing | |
3.6.2 Microbiological testing (excluding sterility testing) | |
LUMIRACOXIB | |
3.1 | Manufacture of Active Substance by Chemical Synthesis |
3.1.1 Manufacture Of Active Substance Intermediates | |
3.1.2 Manufacture Of Crude Active Substance | |
3.1.3 Salt Formation/Purification steps (eg. Crystallisation) Crystallisation | |
3.5 | General Finishing Steps |
3.5.2 Primary Packaging | |
3.5.3 Secondary Packaging | |
3.6 | Quality Control Testing |
3.6.1 Physical / Chemical testing | |
3.6.2 Microbiological testing (excluding sterility testing) | |
PAZOPANIB HYDROCHLORIDE | |
3.1 | Manufacture of Active Substance by Chemical Synthesis |
3.1.1 Manufacture Of Active Substance Intermediates | |
3.1.2 Manufacture Of Crude Active Substance | |
3.1.3 Salt Formation/Purification steps (eg. Crystallisation) Crystallisation | |
3.5 | General Finishing Steps |
3.5.2 Primary Packaging | |
3.5.3 Secondary Packaging | |
3.6 | Quality Control Testing |
3.6.1 Physical / Chemical testing | |
3.6.2 Microbiological testing (excluding sterility testing) | |
TELBIVUDINE | |
3.1 | Manufacture of Active Substance by Chemical Synthesis |
3.1.1 Manufacture Of Active Substance Intermediates | |
3.1.2 Manufacture Of Crude Active Substance | |
3.1.3 Salt Formation/Purification steps (eg. Crystallisation) Crystallisation | |
3.5 | General Finishing Steps |
3.5.2 Primary Packaging | |
3.5.3 Secondary Packaging | |
3.6 | Quality Control Testing |
3.6.1 Physical / Chemical testing | |
3.6.2 Microbiological testing (excluding sterility testing) | |
DICLOFENAC FREE ACID | |
3.1 | Manufacture of Active Substance by Chemical Synthesis |
3.1.1 Manufacture Of Active Substance Intermediates | |
3.1.3 Salt Formation/Purification steps (eg. Crystallisation) Formation of free acid and crystallisation | |
3.5 | General Finishing Steps |
3.5.2 Primary Packaging | |
3.5.3 Secondary Packaging | |
3.6 | Quality Control Testing |
3.6.1 Physical / Chemical testing | |
3.6.2 Microbiological testing (excluding sterility testing) | |
METHYLPHENIDATE HYDROCHLORIDE | |
3.1 | Manufacture of Active Substance by Chemical Synthesis |
3.1.1 Manufacture Of Active Substance Intermediates | |
3.1.2 Manufacture Of Crude Active Substance | |
3.1.3 Salt Formation/Purification steps (eg. Crystallisation) Crystallisation | |
3.5 | General Finishing Steps |
3.5.2 Primary Packaging | |
3.5.3 Secondary Packaging | |
3.6 | Quality Control Testing |
3.6.1 Physical / Chemical testing | |
3.6.2 Microbiological testing (excluding sterility testing) |
12/11/2020 | Name and signature of the authorised person of the Competent Authority of United Kingdom |
Confidential | |
Medicines and Healthcare products Regulatory Agency | |
Tel : Confidential |